Literature DB >> 23257830

VEGF levels and the angiogenic potential of the microenvironment can affect surgical strategy for colorectal liver metastasis.

Clarisse Eveno1, Marc Pocard.   

Abstract

The hypotheses emerging from basic research on colorectal liver metastases must be tested in clinical situations for the adaptation of current treatment strategies. Pre-metastatic niches have been shown to exist in human colorectal synchronous metastases, with the liver parenchyma adjacent to the synchronous liver metastases providing a favorable, angiogenic environment for metastatic tumor growth. The role of the VEGF signaling pathway in liver regeneration and tumor growth remains unclear, but the use of antiangiogenic agents in combination with surgical treatment is almost certainly beneficial.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23257830      PMCID: PMC3547905          DOI: 10.4161/cam.23247

Source DB:  PubMed          Journal:  Cell Adh Migr        ISSN: 1933-6918            Impact factor:   3.405


  28 in total

1.  Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.

Authors:  Frank A Scappaticci; Louis Fehrenbacher; Thomas Cartwright; John D Hainsworth; William Heim; Jordan Berlin; Fairooz Kabbinavar; William Novotny; Somnath Sarkar; Herbert Hurwitz
Journal:  J Surg Oncol       Date:  2005-09-01       Impact factor: 3.454

Review 2.  Role of adjuvant therapy after resection of colorectal cancer liver metastases.

Authors:  Derek G Power; Nancy E Kemeny
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

3.  Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts.

Authors:  D Lyden; A Z Young; D Zagzag; W Yan; W Gerald; R O'Reilly; B L Bader; R O Hynes; Y Zhuang; K Manova; R Benezra
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

Review 4.  Portal vein occlusion before major hepatectomy in patients with colorectal liver metastases: rationale, indications, technical aspects, complications and outcome.

Authors:  C Lim; O Farges
Journal:  J Visc Surg       Date:  2012-04-13       Impact factor: 2.043

5.  Angiogenesis in synchronous and metachronous colorectal liver metastases: the liver as a permissive soil.

Authors:  Gesiena E van der Wal; Annette S H Gouw; Jan A A M Kamps; Henk E Moorlag; Marian L C Bulthuis; Grietje Molema; Koert P de Jong
Journal:  Ann Surg       Date:  2012-01       Impact factor: 12.969

6.  Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone.

Authors:  A P Stillwell; P G Buettner; Y H Ho
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

7.  Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases.

Authors:  Daria Zorzi; Yun Shin Chun; David C Madoff; Eddie K Abdalla; Jean-Nicolas Vauthey
Journal:  Ann Surg Oncol       Date:  2008-07-18       Impact factor: 5.344

8.  Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab.

Authors:  Béatrice Aussilhou; Safi Dokmak; Sandrine Faivre; Valérie Paradis; Valérie Vilgrain; Jacques Belghiti
Journal:  Ann Surg Oncol       Date:  2009-04-11       Impact factor: 5.344

9.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.

Authors:  Rosandra N Kaplan; Rebecca D Riba; Stergios Zacharoulis; Anna H Bramley; Loïc Vincent; Carla Costa; Daniel D MacDonald; David K Jin; Koji Shido; Scott A Kerns; Zhenping Zhu; Daniel Hicklin; Yan Wu; Jeffrey L Port; Nasser Altorki; Elisa R Port; Davide Ruggero; Sergey V Shmelkov; Kristian K Jensen; Shahin Rafii; David Lyden
Journal:  Nature       Date:  2005-12-08       Impact factor: 49.962

10.  Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas.

Authors:  Qingguo Li; Daorong Wang; Jing Li; Ping Chen
Journal:  BMC Cancer       Date:  2011-06-27       Impact factor: 4.430

View more
  7 in total

Review 1.  Hallmarks in colorectal cancer: angiogenesis and cancer stem-like cells.

Authors:  Muriel Mathonnet; Aurelie Perraud; Niki Christou; Hussein Akil; Carole Melin; Serge Battu; Marie-Odile Jauberteau; Yves Denizot
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

2.  VEGF isoforms.

Authors:  Martine Perrot-Applanat
Journal:  Cell Adh Migr       Date:  2012-11-01       Impact factor: 3.405

Review 3.  Potential role of High mobility group box 1 in hepatocellular carcinoma.

Authors:  Rong-Rong Zhou; Xu-Yuan Kuang; Yan Huang; Ning Li; Ming-Xiang Zou; Dao-Lin Tang; Xue-Gong Fan
Journal:  Cell Adh Migr       Date:  2014       Impact factor: 3.405

Review 4.  Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept.

Authors:  Guido Giordano; Antonio Febbraro; Michele Venditti; Serena Campidoglio; Nunzio Olivieri; Katia Raieta; Pietro Parcesepe; Giusy Carmen Imbriani; Andrea Remo; Massimo Pancione
Journal:  Gastroenterol Res Pract       Date:  2014-07-21       Impact factor: 2.260

5.  Interleukin-12 prevents colorectal cancer liver metastases in mice.

Authors:  Fei Shen; Jiang-Lin Li; Weng-Song Cai; Guang-Hui Zhu; Wei-Li Gu; Lin Jia; Bo Xu
Journal:  Onco Targets Ther       Date:  2013-05-13       Impact factor: 4.147

6.  Chitosan oligosaccharides in combination with Agaricus blazei Murill extract reduces hepatoma formation in mice with severe combined immunodeficiency.

Authors:  Ming-Yang Yeh; Hung-Sheng Shang; Hsu-Feng Lu; Jason Chou; Chun Yeh; Jin-Biou Chang; Hsiao-Fang Hung; Wan-Lin Kuo; Lung-Yuan Wu; Jing-Gung Chung
Journal:  Mol Med Rep       Date:  2015-03-09       Impact factor: 2.952

7.  In-Depth Characterization of Mass Spectrometry-Based Proteomic Profiles Revealed Novel Signature Proteins Associated with Liver Metastatic Colorectal Cancers.

Authors:  Xin Ku; Yan Xu; Chunlin Cai; Yili Yang; Long Cui; Wei Yan
Journal:  Anal Cell Pathol (Amst)       Date:  2019-11-04       Impact factor: 2.916

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.